9-Jan-2026
Monte Rosa Therapeutics Prices $300 Million Public Offering
TipRanks (Fri, 9-Jan 5:05 PM ET)
Monte Rosa Therapeutics announces pricing of $300M stock offering
Seeking Alpha News (Fri, 9-Jan 2:20 AM ET)
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Globe Newswire (Thu, 8-Jan 10:49 PM ET)
TipRanks (Thu, 8-Jan 8:40 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanks (Thu, 8-Jan 7:36 AM ET)
TipRanks (Thu, 8-Jan 5:10 AM ET)
Monte Rosa Therapeutics Ends Current ATM Equity Program
TipRanks (Wed, 7-Jan 4:51 PM ET)
Monte Rosa Therapeutics launches $200M public equity offering
Seeking Alpha News (Wed, 7-Jan 4:05 PM ET)
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Wed, 7-Jan 4:01 PM ET)
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
TipRanks (Wed, 7-Jan 12:08 PM ET)
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Monte Rosa Therapeutics trades on the NASDAQ stock market under the symbol GLUE.
As of January 9, 2026, GLUE stock price declined to $24.28 with 4,891,777 million shares trading.
GLUE has a beta of 1.75, meaning it tends to be more sensitive to market movements. GLUE has a correlation of 0.11 to the broad based SPY ETF.
GLUE has a market cap of $1.58 billion. This is considered a Small Cap stock.
Last quarter Monte Rosa Therapeutics reported $13 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, GLUE traded as high as $25.77 and as low as $2.44.
The top ETF exchange traded funds that GLUE belongs to (by Net Assets): XBI, IWM, VTI, AVUV, IWN.
GLUE has outperformed the market in the last year with a price return of +305.3% while the SPY ETF gained +19.0%. GLUE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +187.0% and +40.4%, respectively, while the SPY returned +3.7% and +0.5%, respectively.
GLUE support price is $23.69 and resistance is $26.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLUE shares will trade within this expected range on the day.